Activist Ancora Targets H.B. Fuller, Opposes $1.2B UK Deal

Activist investor Ancora Alternatives is pressuring US adhesives manufacturer H.B. Fuller to abandon a proposed acquisition of UK-based Advanced Medical Solutions Group. Ancora President Jim Chadwick stated the case for this opposition on Bloomberg on 27 May 2026. The investor's intervention frames the $1.2 billion potential deal as a misallocation of capital, arguing H.B. Fuller's core industrial assets present a more compelling value creation opportunity through strategic alternatives, including a potential sale of the entire company. H.B. Fuller's stock closed at $78.45 on 26 May, giving the company a market capitalization of approximately $4.3 billion.

Context — why this activist campaign matters now

Activist campaigns targeting mid-cap industrial firms over M&A strategy have intensified in a higher-for-longer interest rate environment. The last significant campaign in the specialty chemicals space occurred in March 2025, when Engine Capital pushed for the sale of Avient Corporation, resulting in a 22% share price increase over six months. The current macro backdrop features elevated capital costs, with the 10-year Treasury yield at 4.31%, compressing acquisition multiples and increasing scrutiny on deal rationale.

H.B. Fuller’s pursuit of Advanced Medical Solutions, a maker of wound-care adhesives, marks a strategic pivot into higher-margin healthcare markets. This shift triggered Ancora’s campaign. The catalyst chain is direct: Ancora believes the proposed deal destroys shareholder value by diverting capital from core business optimization or a full sale at a premium. The activist sees more immediate value in H.B. Fuller’s established industrial adhesive segments, which serve construction, packaging, and electronics.

The timing coincides with sector-wide consolidation pressure. Larger peers like Henkel and 3M have streamlined portfolios, creating acquisition opportunities for scaled players. Ancora’s argument hinges on the premise that H.B. Fuller itself is a more attractive asset for a strategic buyer than it is an acquirer of a UK medical firm. This places the board in a direct conflict over the fundamental direction of the 135-year-old company.

Data — what the numbers show

H.B. Fuller's financial metrics provide the quantitative battleground. The company reported fiscal 2025 revenue of $3.51 billion, with an adjusted EBITDA margin of 14.2%. Its net debt stood at $1.48 billion as of its last quarterly filing, representing a leverage ratio of 2.7x EBITDA. The proposed acquisition of Advanced Medical Solutions, valued at roughly $1.2 billion, would represent a transaction worth over 25% of H.B. Fuller's own market cap.

The deal premium is a focal point. Advanced Medical Solutions' London-listed shares traded at a 30-day volume-weighted average price of 245 pence before deal rumors surfaced. A $1.2 billion offer implies a significant premium, estimated between 35% and 50%. This premium would be funded through new debt, materially increasing H.B. Fuller's use. Post-acquisition, pro forma net debt could exceed $2.6 billion, pushing use toward 4.0x EBITDA based on combined trailing earnings.

A comparison of valuation multiples reveals the strategic disconnect. H.B. Fuller trades at an enterprise value to EBITDA multiple of 9.5x. Pure-play medical device adhesive companies command multiples between 12x and 15x. Ancora's thesis suggests the market assigns H.B. Fuller a conglomerate discount; shedding non-core assets or selling the whole company could unlock value closer to 11x EBITDA, a 16% upside to the current share price. The stock's performance lags the Materials Select Sector SPDR Fund year-to-date, which is up 4.1% versus H.B. Fuller's 1.8% gain.

Analysis — what it means for markets / sectors / tickers

The campaign creates immediate second-order effects across the industrial and healthcare adhesive landscape. Direct beneficiaries of a blocked deal include other potential acquirers of Advanced Medical Solutions, such as Convatec Group or Smith & Nephew, whose shares could see positive momentum if the UK firm remains independent. Within H.B. Fuller's peer set, companies like Arkema and Sika may benefit from reduced competitive pressure in industrial markets if H.B. Fuller remains focused or is acquired.

Potential losers include Advanced Medical Solutions, whose share price could correct by 15-25% if the deal collapses, reflecting the lost premium. Other specialty chemical firms contemplating transformative healthcare deals may face increased investor scrutiny, potentially dampening M&A activity in the sector. A successful push by Ancora for a full sale of H.B. Fuller would likely benefit shareholders through a control premium, but could negatively impact bondholders due to increased use under a new, potentially financial, owner.

A key counter-argument to Ancora's position is that H.B. Fuller's growth in mature industrial markets is limited. The pivot into higher-growth, higher-margin medical adhesives offers a credible long-term path to improved profitability and multiple expansion. The healthcare sector's defensive characteristics could also provide earnings stability during an economic downturn, an attribute valued in the current uncertain climate.

Positioning data indicates mixed initial reactions. Options flow shows increased buying of H.B. Fuller call options for July and September, suggesting some traders anticipate a positive resolution for shareholders. Short interest in the stock remains elevated at 5.2% of float, indicating a cohort of investors are skeptical of both the deal and the company's standalone prospects. Flow into the iShares U.S. Industrials ETF has been neutral, suggesting the event is viewed as idiosyncratic.

Outlook — what to watch next

The immediate catalyst is H.B. Fuller's formal response to Ancora, expected within 10 business days. The company must decide whether to engage with the activist, proceed with the deal announcement, or abandon the acquisition. A shareholder vote on the deal, if pursued, would likely occur in late July or early August 2026, following regulatory filings.

Key levels to watch include H.B. Fuller's stock price resistance at $82.50, its 200-day moving average. A sustained break above this level would signal market confidence in Ancora's agenda. Conversely, support sits at $76.00, the early May low. For Advanced Medical Solutions, the 250 pence per share level is critical; a break below would indicate the market is pricing in deal failure.

The next earnings catalyst is H.B. Fuller's fiscal second-quarter report, scheduled for 24 June 2026. Management commentary on capital allocation and portfolio strategy will be scrutinized for any shift in tone. Ancora may also file a detailed white paper or Schedule 13D amendment outlining its specific operational and financial proposals for the company, which would set the stage for a potential proxy contest.

Frequently Asked Questions

What does the H.B. Fuller activist situation mean for retail investors?